title: The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy.
abstract: BACKGROUND
  In this study, we investigated whether such a discontinuation of oral bisphosphonate (BP) for 3 months might influence the incidence of BP-related osteonecrosis of the jaw (BRONJ) and wound healing after tooth extraction in patients receiving oral BP therapy.
  
  
  METHODS
  There were a total of 434 teeth in 201 patients (18 males and 183 females). The patients were divided into two groups depending on whether or not they underwent a 3-month discontinuation of BP therapy (BP- and BP+) before tooth extraction. In this observational study investigated delayed wound healing after tooth extraction in patients receiving oral BP therapy.
  
  
  RESULTS
  In all cases of the BP- group, there were no BRONJ although there was delayed wound healing in two cases. However, in one case of the BP+ group, oral BP was continued because it was deemed high risk to discontinue treatment by the patient's physician. In this case, an intraoral fistula was still present with bone exposure at 120 weeks after extraction (BRONJ stage 1).
  
  
  CONCLUSIONS
  This study supports the idea of a drug holiday and encourages further clinical research on this topic of tooth extraction in patients receiving oral BP therapy.
authors: Department of Oral and Maxillofacial Surgery, Kakogawa East City Hospital (Chief: Dr. Ri Shinshou), Kakogawa, Japan. Electronic address: hasetaku@med.kobe-u.ac.jp.
authors: Takumi
authors: T
authors: Hasegawa
authors: Shinshou
authors: S
authors: Ri
authors: Masahiro
authors: M
authors: Umeda
authors: Hideki
authors: H
authors: Komatsubara
authors: Masaki
authors: M
authors: Kobayashi
authors: Takashi
authors: T
authors: Shigeta
authors: Izumi
authors: I
authors: Yoshitomi
authors: Hisazumi
authors: H
authors: Ikeda
authors: Yasuyuki
authors: Y
authors: Shibuya
authors: Izumi
authors: I
authors: Asahina
authors: Takahide
authors: T
authors: Komori
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage; D019072:Antibiotic Prophylaxis; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000517:prevention & control; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D003731:Dental Caries / Q000601:surgery; D004164:Diphosphonates / Q000008:administration & dosage*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016155:Oral Fistula / Q000209:etiology; D010485:Periapical Periodontitis / Q000601:surgery; D010518:Periodontitis / Q000601:surgery; D000068296:Risedronic Acid; D012307:Risk Factors; D013997:Time Factors; D014081:Tooth Extraction / Q000379:methods; D014945:Wound Healing / Q000187:drug effects
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate
keywords: Bisphosphonate; Bisphosphonate related osteonecrosis of jaw; Oral bisphosphonate; Tooth extraction